Trials of venous thromboembolism prevention

被引：5

作者：

Norrie, John ^{[1
]}

机构：

[1] Univ Aberdeen, CHaRT, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland

来源：

LANCET | 2007年 / 370卷 / 9591期

关键词：

D O I：

10.1016/S0140-6736(07)61425-1

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：915 / 917

页数：3

共 12 条

[1]

The challenges of new drugs benefits and risks analysis: Lessons from the ximelagatran FDA Cardiovascular Advisory Committee [J].

Boudes, Pol F. .

CONTEMPORARY CLINICAL TRIALS, 2006, 27 (05) :432-440

[2]

Committee for Proprietary Medicinal Products (CPMP), 2003, POINTS CONS ADJ BAS

[3]

*CPMP, 2005, REC NEED REV GUID CL

[4]

*CPMP, 2006, DRAFT GUID CLIN INV

[5]

*CPMP, 2000, POINTS CONS CLIN INV

[6]

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].

Eriksson, Bengt I. ;

Dahl, Ola E. ;

Rosencher, Nadia ;

Kurth, Andreas A. ;

van Dijk, C. Niek ;

Frostick, Simon P. ;

Prins, Martin H. ;

Hettiarachchi, Rohan ;

Hantel, Stefan ;

Schnee, Janet ;

Bueller, Harry R. .

LANCET, 2007, 370 (9591) :949-956

[7]

Prevention of venous thromboembolism [J].

Geerts, WH ;

Heit, JA ;

Clagett, GP ;

Pineo, GF ;

Colwell, CW ;

Anderson, FA ;

Wheeler, HB .

CHEST, 2001, 119 (01) :132S-175S

[8]

Goodacre S, 2006, HEALTH TECHNOL ASSES, V10, P1

[9]

The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests [J].

Kassaï, B ;

Shah, NR ;

Leizorovicza, A ;

Cucherat, M ;

Gueyffier, F ;

Boissel, JP .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2005, 58 (10) :1042-1051

[10]

Thromboembolism prevention in ischaemic stroke [J].

O'Donnell, Martin ;

Kearon, Clive .

LANCET, 2007, 369 (9571) :1413-1415

← 1 2 →